Filter By Product Search for
AKT1
Loading...
AKT1 Full Name
v-akt murine thymoma viral oncogene homolog 1
AKT1 Introduction
AKT1 Signaling Pathway has become one of the most intensively studied molecular pathways in cancer biology because it sits at the center of how cells respond to growth signals, metabolic stress, and environmental damage. AKT1, also known as protein kinase B alpha, is a serine/threonine kinase that regulates critical cellular activities including proliferation, glucose metabolism, protein synthesis, apoptosis resistance, and angiogenesis. In healthy tissues, AKT1 activity is tightly controlled through the PI3K/AKT/mTOR pathway to maintain balanced cell survival and tissue repair. However, abnormal AKT1 activation can drive uncontrolled cell growth and therapeutic resistance, making it a major concern for researchers and clinicians developing targeted therapies. Many patients with aggressive or recurrent tumors experience treatment failure because hyperactivated AKT1 signaling allows cancer cells to evade apoptosis and adapt to hostile microenvironments, highlighting why AKT1 remains a high-priority therapeutic target across precision oncology programs.
Recent research has revealed that AKT1 is far more than a simple growth-promoting kinase. Emerging studies demonstrate that AKT1 actively rewires tumor metabolism, allowing malignant cells to survive under nutrient deprivation and hypoxic conditions. Investigators have shown that AKT1-mediated phosphorylation events can redirect metabolic enzymes toward glycolysis, supporting the "Warburg effect" commonly observed in rapidly proliferating cancers. This metabolic switch enables tumor cells to generate energy and biosynthetic intermediates more efficiently, promoting continued tumor expansion and resistance to stress. Beyond metabolism, AKT1 signaling also influences oxidative stress adaptation, DNA damage responses, and interactions with membrane-associated proteins such as Caveolin-1 and Src. These discoveries are particularly relevant for patients facing chemotherapy or radiotherapy resistance, since persistent AKT1 activation has been associated with enhanced antioxidant defenses and reduced treatment sensitivity in several malignancies, including rhabdomyosarcoma and breast cancer.
The clinical complexity of AKT1 became even more apparent after the discovery of the hotspot E17K mutation, one of the best-characterized activating mutations in solid tumors. Although AKT1 E17K promotes oncogenic signaling in cancers such as breast, colorectal, and ovarian cancer, researchers have also observed paradoxical effects in certain biological contexts. Some studies suggest that the mutation may suppress cancer cell migration and metastatic behavior by interfering with β-catenin signaling and strengthening epithelial cell adhesion through increased E-cadherin expression. This dual behavior has generated significant interest in understanding how AKT1 mutations influence tumor progression, prognosis, and therapeutic response in different tissue environments. As precision medicine continues to evolve, AKT1 is increasingly viewed not only as a cancer-driving oncogene but also as a biomarker for patient stratification, targeted inhibitor development, and combination therapy design aimed at overcoming drug resistance and improving long-term clinical outcomes.
Alternate Names for AKT1
AKT1
v-akt murine thymoma viral oncogene homolog 1
RAC-alpha serine/threonine-protein kinase
AKT
PKB
PRKBA
RAC
PKB alpha
RAC-PK-alpha
proto-oncogene c-Akt
protein kinase B alpha
rac protein kinase alpha
PKB-ALPHA
RAC-ALPHA
MGC99656
Cell Signaling
